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Dengue virus (DENV) has four serotypes, which can cause from asymptomatic disease
to severe dengue. Heterologous secondary infections have been associated to a greater
risk of potentially fatal dengue due to non-neutralizing memory antibodies (Abs), which
facilitate the infection, such as anti-precursor membrane (prM) Abs, among other mech-
anisms. Usually, class-switched memory Abs are generated mainly through germinal
centers (GCs). However, the cellular events underlying these Ab responses to DENV,
especially during repeated/secondary infections, have been poorly studied. We wanted
to know whether there is involvement of GC reactions during cutaneous DENV infection
and whether there is any sort of preferential Ab responses to defined viral proteins.
Intradermal DENV inoculation at a relatively low dose efficiently infects immune-competent
BALB/c mice, inducing higher quantities of DENV-specific GC B cells and larger GCs than
the control conditions. Interestingly, GCs exhibited as much prM as envelope (E) and
non-structural 3 viral proteins in situ. Intriguingly, despite the much larger abundance of
E protein than of prM protein in the virions, infected animals showed similar amounts
of circulating Abs and Ag-specific GC B cells both for prM and for E proteins, even
significantly higher for prM. To the best of our knowledge, there are no reports of the
GC responses during DENV infection. This relatively stronger anti-prM response could
be triggered by DENV to preferentially promote Abs against certain viral proteins, which
might favor infections by facilitating DENV invasion of host cells. It is thus conceivably that
DENV might have evolved to induce this kind of Ab responses.
Keywords: dengue virus, in vivo B cell responses, germinal centers, antibodies
Introduction
Dengue virus (DENV) is one of the most significant human viral pathogens transmitted by
mosquitoes and causes every year between 50 and 100 million infections worldwide, resulting
in approximately 500,000 people with severe dengue (SD). It is estimated that over 40% of the
Abbreviations: C6/36, supernatant from uninfected C6/36 mosquito cell line; DAB, diaminobenzidine; DENV, dengue virus;
DLN, draining lymph node; E, envelope; EDI-III, envelope domain I-III; i.d., intradermal; iDENV, inactivated dengue virus;
IHC, immunohistochemistry; MBC, memory B cells; NS, non-structural; PNA, peanut agglutinin; prM, precursor membrane;
SD, severe dengue.
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world’s population is now at risk of infection. Dengue is caused
by four serotypes (DENV1-4) circulating in tropical and sub-
tropical regions of the world. It is believed that the vast majority
of dengue infections are asymptomatic; however, a proportion
manifests a non-specific febrile illness or progresses to classical
dengue fever, characterized by fever and severe joint pain. Some
of those infections can evolve to SD, dengue haemorrhagic fever
(DHF), or dengue shock syndrome (DSS) (1). Various mecha-
nisms have been associated with SD disease, highlighting among
them the heterologous secondary infection, due to pre-existing,
sub-, or non-neutralizingmemory antibodies (Abs) (2). Although
this hypothesis was proposed decades ago, it is only recently
that detailed experimental proofs were provided in humans.
Researchers finally unraveled that the so called facilitating Abs are
directed mainly against the precursor membrane (prM) protein
(3, 4). Interestingly, the prM is abundant on immature and non-
infectious virions, but not in the mature particles (5–7).
Dengue virus contains three structural proteins, capsid, enve-
lope (E), and membrane. Membrane protein is first formed as a
precursor called prM (8, 9). The maturation process of DENV
is directed by the proteolytic cleavage of the prM, producing
then totally infectious particles (7, 10, 11). However, this mech-
anism is not completely efficient, and fully immature or partially
mature virions are produced by host cells (5). Immature status
depends on the prM cleavage, modifying size and morphology of
the particles. At least 30–40% of DENV particles released from
infected mosquito cells are immature, containing different quan-
tities of prM (6). In the presence of non-neutralizing anti-prM
Abs, even immature and non-infectious virus can enter the cells
via Fc gamma receptors (FcγR) and replicate efficiently, leading
to more infected cells, potentially contributing to a more severe
disease (12, 13). On the other hand, E protein has three domains
(EDI-III) (14), and it is known that EDIII is involved in virus
attachment to host cell surface (15). Now, it is also known that
neutralizing Abs are preferentially directed to EDIII, and recent
findings have shown that Abs to EDI or EDII could facilitate
DENV infection when present at sub-neutralizing concentrations
(16, 17). Likewise, Abs to structural protein E can also behave as
facilitating ones by enhancing infectivity of immature or partially
mature particles due to recognition of epitopes that are exposed in
immature virions (18, 19). In addition to the potential facilitating
effects of these Abs, those that are indeed neutralizers seem to
be directed against complex conformational epitopes, which are
apparently expressed only when proteins are already assembled
on a mature virus particle, therefore it has been complicated to
dissect the precise antigenic nature of these structures (20).
Regarding the cell biology of Ab production, it is known that
Abs, which had matured their affinity and had changed their
isotype, are originated mainly through germinal center (GC)
reactions. The GC is a very complex microenvironment where
clonal B cell expansion and selection occurs in response to T-
cell dependent antigens (Ag). Two crucial molecular mechanisms
are utilized in the GCs, somatic hypermutation, and class switch
recombination. The outcome of the GC reaction is the generation
of Ab-secreting cells or plasma cells (PCs), and memory B cells
(MBC), thus developing both immediate as well as long-term
protection against re-infections (21–23). Long-lived PCs home to
bone marrow, where they find niches for survival, and secrete
increased affinity Abs (24). On the other hand, MBC activation
is faster thus providing rapid protection against re-exposure to
potentially dangerous Ags, differentiating then to PC, generating
long-lasting B cell immunity (25). However, in DENV infection,
long-lived PC and MBC are apparently “responsible” for the
production of infection-facilitating Abs (26–28). Released Abs
by these PCs should neutralize DENV, as apparently occurs in
the case of homologous reinfections. In contrast, in the case of
heterologous DENV infections, pre-existing Abs can facilitate the
viral invasion of host cells. Therefore, we wanted to knowwhether
DENV would be inducing any sort of preferential Ab responses
to defined DENV Ags during crucial cellular events of in vivo Ab
generation such as the GC reaction. To ascertain if that happens,
we assessed whether GC reactions ensue the cutaneous DENV
inoculation in immune-competent mice. Of note, although there
are some few studies using immune-competent mice (29–32),
up to now the standard animal model to study DENV infection
in vivo is mostly limited to immune-deficient mice (33), and as
far as we know, no existing model yet has used the skin as route
to infect in vivo. Therefore, we propose a model of cutaneous
infection using immune-competent animals, which can normally
react to and recognize theDENVAgs.We found a similar response
to E, prM, and non-structural (NS) 3 DENV proteins, despite
the much bigger abundance of E protein in the viral particles. In
addition, the response was significantly higher for the prM than
for the E viral protein. It is conceivable that DENV has evolved
to trigger this kind of Ab responses to preferentially promote
infection-facilitating Abs.
Materials and Methods
Mice and Immunizations
Specific pathogen-free male BALB/c mice 6- to 8-week-old from
the breeding facilities of the Center for Advanced Research, The
National Polytechnic Institute (CINVESTAV-IPN) were intrader-
mally (i.d.) injected in the inguinal area with 6 104 plaque
forming units (pfu) of active DENV. Control mice were inoc-
ulated with the same dose of UV-inactivated-DENV, or super-
natant from uninfected C6/36 mosquito cell line (C6/36), or ster-
ile endotoxin-free phosphate buffered saline (PBS). Experiments
were performed in accordance with the institutional guidelines
for animal care and experimentation (CINVESTAV-IPN). Two or
more independent experiments were performed, and at least three
mice per group were sacrificed at each selected time point (7, 14,
and 28 days post-inoculation). In some experiments, mice were
i.d. inoculated with ovalbumin (20 µg). For each experimental
condition,mice were inoculated at day 0 and a challengewas given
at day 7. For FACS analyses, animals were sacrificed at day 14.
Preparation of Viral Stock
The DENV2 clinical isolate was described previously (34). C6/36
mosquito cell line was grown in minimal essential medium
(MEM) supplemented with 10% fetal bovine serum (FBS) (Gibco,
Carlsbad, CA, USA) at 34°C. Baby hamster kidney (BHK-21) cells
were cultured at 37°C in the presence of 5% CO2 in MEM supple-
mented with 10% FBS, 1 IU/mL penicillin, 1 µg/mL streptomycin,
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and 2.4 ng/mL amphotericin B. Virus stock was prepared by
infecting the C6/36 cell monolayer. After 48–72 h, the infected
monolayers were homogenized and diluted in 40% polyethylene
glycol solution in 2M NaCl (Sigma-Aldrich, St. Louis, MO, USA)
and incubated at 4°C overnight. The suspension was centrifuged
at 20,000 g for 1 h. The viruses were then resuspended in 1/15 of
the total volume in a glycine buffer (50mM tris, 200mM glycine,
100mM NaCl, and 1mM EDTA) and 1/30 of the total volume
in FBS. The viruses were homogenized, aliquoted, and frozen at
 80°C until use. The viral stocks were titrated using a standard
plaque-forming assay technique with BHK-21 cells, as described
previously (35). To use C6/36 cells as a negative control, we imple-
mented the same culture procedure but without infecting the cells
with DENV2. For DENV inactivation, virus was exposed to UV
radiation (three cycles, 3min: 254 nm; 1000 J/m2). Inactivation of
virus infectivity was verified by plaque assay on BHK-21 cells.
Recombinant Viral Proteins and Production of Ag
Multimers
Cultures of transformed-Escherichia coli strain BL21 with the
recombinant plasmids containing E protein (36) and NS3 protein
(37) sequence from DENV2 were induced for proteins expression
by the addition of 1mM isopropyl thiogalactoside (IPTG). The
inclusion bodies were prepared and fusion proteins were then
purified from a 10% preparative SDS-PAGE gel, as described
previously (38). For the prM protein, PCR product encoding the
full-length prM protein from DENV2 NG was cloned into the
plasmid pPROEX HTa. The prM sequence was amplified by PCR
using the primers: (forward) 50 (HindIII) ccggaattcttccatttaacca-
cacgt and 30 (XhoI) aagcggccgcaatgtcattgaagg (backward) 50. Both
the plasmid and the PCR product were digested withHindIII and
XhoI, purified, and then ligated into the corresponding restriction
sites of the mentioned parental vector. The resultant plasmid
was named pPROEX/prM. The recombinant plasmid directs the
synthesis of DENV2 prM protein fusion followed by a histidine
tag encoded by the vector. Then, the recombinant plasmid was
purified from E. coli JM109 with the endo-free plasmids kit (Qia-
gen Inc., Chatsworth, CA, USA). The constructs were verified by
automated sequencing. Finally, the expression of the recombinant
protein was demonstrated by the presence of a protein with the
predicted molecular weight of 25 kDa. Purified proteins were
biotinylated using a Biotin-7-NHS kit (Roche 11 418 165 001)
at 2mg/ml DMSO, using 30 µg of biotin/1mg of target protein.
To prepare the Ag multimers, biotinylated protein was held with
Streptavidin-Pacific Blue (Sav-PB) (Invitrogen S11222) in a 6:1
(recombinant protein:Sav-PB) ratio for 30min at room tempera-
ture (rt). The Ag multimer fraction was centrifuged in a 100-kDa
molecular weight cutoff Amicon Ultra filter (Millipore) (39).
Production of Antibodies Specific for E, prM, and
NS3 Viral Proteins
Rats (6- to 8-week-old) and rabbits (10-week-old/1.8 kg) were
obtained from the animal facilities of CINVESTAV-IPN. Animals
were immunized with four doses of 50 µg of recombinant proteins
(prM-his and NS3-gst in rats; E-gst in rabbits). These immuniza-
tions were administered subcutaneously with incomplete Freund’s
adjuvant. After the third immunization, sera were screened by
ELISA. Polyclonal anti-sera were adsorbed on tissue from mice,
titrated and used for immunohistochemistry (IHC).
Cell Suspensions of Draining Lymph Nodes and
Flow Cytometry Analysis
At each indicated time point, the animals were sacrificed and
inguinal draining lymph nodes (DLNs) were carefully dissected
and collected in PBS with 0.1% of bovine serum albumin (US Bio-
logical A1310-05). Tissues were homogenized, and viability of the
cells was determined by trypan blue exclusion. Cell suspensions
were analyzed by flow cytometry. Abs and reactants used were:
anti-CD19-APC (Rat IgG2a, BD Biosciences 557399), anti-IgD-
PE (Rat IgG2a, eBioscience 12-5993-83), Peanut agglutinin lectin-
FITC (PNA-FITC, Vector FL-1071), and Agmultimers (prM-Sav-
PB, E-Sav-PB or NS3-Sav-PB). Cells were treated with universal
blocking reagent (BiogenexHK085-5K), then incubated with Abs,
PNA-FITC, and Ag multimers for 20min at rt in the dark, and
then washed. Finally, cells were fixed with 1% paraformaldehyde
and analyzed in a Beckman Coulter Cyan Cytometer using Sum-
mit software. Results were analyzed with FlowJo software v7.6.5
(Tree Star).
Immunohistochemistry
Draining lymph nodes were obtained at different time points
(days 7, 14, and 28) post-inoculation and frozen in tissue freez-
ing medium (Tissue-Tek® O.C.T. Compound, Sakura® Finetek).
Four to six micrometers of DLN-sections were mounted on poly
-Lysine charged slides. Endogenous peroxidase was blocked
with 9% of H2O2 in PBS for 30min at 37°C. DLN sections
were incubated with the primary Abs (rabbit anti-E, rat anti-
prM, or rat anti-NS3) overnight at 4°C. HRP-secondary Abs
(anti-Rat Jackson Labs 112-035-143, and anti-Rabbit Jackson
Labs 111-036-047) were used during 1 h at rt to detect the pri-
mary bound Ab. Enzyme-linked Abs were revealed with 3,30-
diaminobenzidine/H2O2 for 10–15min at rt. To detect GCs,
DLN sections were incubated with biotinylated-PNA (Vector B-
1075), followed by HRP-conjugated streptavidin (Pierce 21124).
Enzyme-linked streptavidin was revealed with Vector SG (Vec-
tor SG substrate Kit SK-4700). For double immunolabeling, the
slides were treated again with H2O2, after the primary staining
as above, to quench the specifically bound HRP. No counter-
stain was performed and the slides were mounted in polymount
resin. Results were recorded using Image-Pro PLUS software for
the Olympus BX51 system microscope. Pictures from the DLN
and non-DLN (contralateral inguinal LN) were captured and the
size was analyzed by ImageJ 1.47v (National Institutes of Health,
NIH, USA).
Serum Antibody Measurement (ELISA)
To measure DENV Ag-specific Abs (anti-E, anti-prM) in the dif-
ferent experimental conditions, serum was collected at different
time points post-inoculation. Anesthetized-micewere bled by car-
diac puncture.Ninety-sixwell E.I.A./R.I.A. immunoplates (Costar
3590, Cambridge, MA, USA) were coated with Ag multimers of
protein E or protein prM (1 µg/ml) overnight at 4°C in a moist
chamber. After washing and blocking, serial dilutions of serum
samples were incubated for 2 h at 37°C. After further washes,
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HRP-conjugated anti-mouse IgG (Bio Rad 170-6516) was added
for 2 h at 37°C. The reaction was visualized by the addition of 2,20-
Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium
salt (ABTS) substrate (Sigma-Aldrich A1888). The absorbance
was measured at 405 nm in a Sunrise Tecan microplate reader,
software Magellan v.3.0 (Switzerland). Relative Ab titers were
calculated after plotting the optical density of each well against
the serum dilution and were derived from the linear portion of
the resulting curves.
Statistical Analysis
Values were expressed asmean SEM.Differences betweenmean
values were analyzed for statistical significance with GraphPad
Prism 5 Software (La Jolla, CA, USA), using unpaired two-tailed
Student’s t-test, and two-way analysis of variance (ANOVA) with
the Bonferroni post-test. P-values <0.05 were considered statisti-
cally significant (*P< 0.05; **P< 0.01; ***P< 0.001).
Results
DENV Efficiently Infects Immune-Competent
Mice via the Skin
To explore whether the cutaneous route can be used to infect
immune-competent BALB/c mice with DENV, animals were
intradermally (i.d) inoculated either with active DENV (DENV2,
obtained from a clinical isolate from the National Institute for
Epidemiological References INDRE, Minister of Health Mexico),
with UV-inactivated DENV (iDENV), with supernatant from
uninfected C6/36 mosquito cell line (C6/36, these are deemed
the “gold standard” cells to easily propagate DENV), or with
endotoxin-free PBS. DENV-inoculated mice showed significantly
bigger DLNs than control conditions at different time points post-
inoculation (Figures 1A–C). When we compared these differ-
ences by the ratio of DLN over non-DLN (contralateral inguinal
LN) in these mice, DENV induced significantly larger DLNs than
the control conditions. The cellularity obtained per DLN was
higher inDENV-inoculatedmice, confirming the findings regard-
ing DLN size post-inoculation (Figure 1D). These results sug-
gested that DENV is actively infecting immune-competent mice
and inducing an immune response. To confirm a productive infec-
tion, we searched for the NS3 viral protein in the DLNs since it has
been reported that, among the sevenNSproteins,NS3 andNS5 are
involved in viral RNA replication, thus their presence is indicative
of viral replication (40, 41). From 7 days post-inoculation, NS3
viral protein was found in DLN, and was preferentially distributed
in the cortical zone. The staining distribution for NS3 was dis-
played on single positive cells and in a reticular pattern inside B
cell follicles (Figures 1E–J). We observed the highest intensity of
NS3 staining at day 14 post-infection (Figures 1G,H). At 28 days,
the labeling was scarce but still detectable (Figures 1I,J). In addi-
tion, during the first week post DENV-inoculation, mice seemed
to be in discomfort, and exhibited some piloerection, altogether
indicating an active DENV infection process. Pre-immune serum
fromnon-immunized rat was used as isotype control Ab for in situ
NS3 detection (Figure S1 in Supplementary Material).
DENV But Not the Control Conditions Induced
the Largest GCs in Immune-Competent Mice
The presence of IgG (memory) Abs to DENV infection in humans
and mice suggests that these Abs came from a GC reaction, and
FIGURE 1 | Cutaneous inoculation of DENV infects immune-
competent mice inducing an immune response. The size of draining
lymph nodes (DLN) and non-DLN (contralateral inguinal LN) was compared
among groups of immune-competent BALB/c mice inoculated with either
intact DENV, UV-inactivated-DENV (iDENV), supernatant from uninfected
C6/36 mosquito cell line (C6/36), or endotoxin-free PBS. (A) DENV induces
the biggest DLNs post-inoculation (14 days post-inoculation). (B,C) The ratio
between the sizes of these LN (DLN/Non -DLN) at days 7, 14, and 28
post-inoculation. (D) The cellularity obtained per DLN at day 14
post-inoculation was higher in DENV inoculated mice than in mice inoculated
with the other conditions. Data shown are pooled from three independent
experiments, and represent the meanSEM. (E–J) NS3 viral protein was
identified by means of immunohistochemistry (IHC, DAB, gray color) in DLN
from DENV-infected mice at different time points post-inoculation [day 7 (E,F);
day 14 (G,H); day 28 (I,J)]. Pictures in (F,H,J) (60, scale bar 40 µm)
correspond to the squares indicated on the left: (E,G,I) (10, scale bar
200 µm). Representative pictures from one of three independent experiments
are shown. Mice were inoculated i.d. with 6104 pfu of DENV or the other
conditions at day 0, boosted at day 7, and sacrificed at the indicated days.
Dotted lines depict the limits of LNs. Data were analyzed with unpaired
two-tailed Student’s t-test, and two-way ANOVA with the Bonferroni post-test.
*P<0.05, **P<0.01, ***P<0.001.
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FIGURE 2 | Cutaneous DENV induces an increased number and size of
GCs compared with control conditions. (A–L) DLNs from mice inoculated
i.d. with DENV (A,E,I), iDENV (B,F,J), C6/36 (C,G,K), or PBS (D,H,L) and
collected at 7 (A–D), 14 (E–H), and 28 (I–L) days post-inoculation show an
increased number and bigger GCs in animals infected with DENV compared
with the other conditions. The limits of LN are indicated by dotted lines.
Arrowheads indicate GCs, labeled in situ with PNA and revealed in blue-gray
color (SG Vector). Representative pictures from one of three independent
experiments are shown. Mice were inoculated at day 0 and boosted at day 7.
(M) The kinetic of GCs area as percentage of GCs Area over Total LN Area in
each condition is shown. Data shown are pooled from three independent
experiments, represent the meanSEM, and were analyzed with two-way
ANOVA with the Bonferroni post-test. *P<0.05, **P<0.01, ***P<0.001.
Scale bar, 500 µm.
therefore that DENV infection is inducing GC responses. To test
this, we assessed inDLNswhether GC reactions ensued cutaneous
DENV inoculation. PNA labeling in situ within DLN showed that
DENV induces a stronger GC response compared with animals
receiving the different control inoculum. DENV-induced GCs
were of larger number and size thanGCs under control conditions
such as iDENV, C6/36, or PBS (Figure 2). When we followed up
the kinetics of GC area per tissue section during the infection, we
found that the peak of this response was reached at day 14 post-
inoculation of cutaneous DENV (Figure 2M). To quantify the
number of GC B cells among the different experimental groups,
we carried out flow cytometry analysis of DLN cell suspensions.
GC B cells can be identified by the binding of PNA, the loss of
surface IgD, and the positivity for the B cell restricted marker
CD19, we thus looked for IgD CD19+PNA+ B cells (Figure
S2 in Supplementary Material). DENV infection increased the
absolute amount of GC B cells in DLN even over the GC B cells
quantities induced by ovalbumin (OVA), a non-infectious Ag
well-known inducer of GCs (Figure 3). The numbers of GCB cells
per LNwere about twice higher in DENV-inoculatedmice than in
OVA-inoculated mice.
The Immune Response to E and to prM Viral
Proteins is Comparable in DENV-Infected Mice
The Ab response to E viral protein in DENV infection has been
studied in more detail due to their neutralizing features (42).
However, although the prM Ag is also exposed on immature
viral particles constituting around 40% of virions (6), the Ab
response against the prM has been poorly explored despite the
fact that a high proportion of the DENV infection-enhancing
Abs are now known to be directed mostly to the prM (4, 16). To
determine whether these GC responses could be related to these
two proteins, we searched in situ for the E and the prM inside
DLN of cutaneously inoculated mice. By IHC, we found both
FIGURE 3 | Cutaneous DENV inoculation induces an increased
quantity of GC B cells (IgD CD19+PNA+) in DLNs compared to
control conditions. (A) Representative flow cytometry plots indicate GC B
cells percentage per each experimental condition described. Live IgD 
singlets (not shown) were gated on GC (CD19+PNA+) cells. Mice were i.d.
inoculated with DENV, iDENV, C6/36, OVA, or PBS at day 0 and boosted at
day 7. At day 14, post-inoculation cell suspensions from DLN were labeled for
GC B cells. DENV inoculation induced the biggest percentage (B), and the
highest quantity of GC B cells per DLN (C). OVA was used as positive control
for GCs induction. Data shown are pooled from three to six independent
experiments, represent the meanSEM, and were analyzed with unpaired
two-tailed Student’s t-test. *P<0.05, **P<0.01, ***P<0.001.
Ags. The positive signal for E viral protein was distributed along
the whole DLN, depicting an endothelial-like structure, especially
surrounding the follicles and GCs. In addition, it was possible to
find the E viral protein inside GCs too (Figure 4; Figure S3 in Sup-
plementaryMaterial). Unlike E staining, the positive signal for the
prM showed a restricted location inside B cell follicles, with some
positive cells revealing a dendritic morphology. The intensity of
prM labeling was comparable with that of the E protein inside
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FIGURE 4 | In situ distribution of DENV proteins inside GCs in DLN.
The viral proteins E [DENV: (A–F), iDENV: (M–R)] and prM [DENV: (G–L),
iDENV: (S–X); DAB, brown color] were ascertained in a concomitant double
staining for GCs (PNA; SG, blue-gray color) in DLN at day 7, 14, and 28
post-cutaneous DENV-(A–L) and iDENV-inoculation (M–X). E protein
staining depicts a vascular-like pattern around GCs [arrows in
(B,D,F,N,P,R)], unlike prM staining which shows single positive cells [arrows
in (H,J,L,T,V)]. In the case of iDENV, the proteins distribution was scant. At
day 28, the intensity of the staining diminished, and prM positive cells were
fewer. For each time point, right images (60, scale bar 40 µm, T)
correspond to the squares indicated on the left (10, scale bar 200 µm, S).
Dotted lines indicate the limits of LNs. Representative pictures from one of
three independent experiments are shown. Mice were inoculated at day 0
and boosted at day 7.
the GC. In the case of iDENV, the signal for these proteins was
very much weaker than that of the active DENV at the same time
points assessed. Trying to support these data from another angle,
we determined the amounts of prM- and E-specific GC B cells
by flow cytometry using DENV Ag-multimers. We found similar
amounts of E-specific GC B cells and of prM-specific GC B cells,
even significantly higher for prM (Figure 5A). Furthermore, the
relative titer of circulating Abs was also significantly higher for the
prMprotein than for the E protein in animals that were inoculated
with DENV (Figure 5B). Altogether, these results suggest that
the magnitude of the Ab response to prM and E viral proteins is
similar, despite the much smaller amounts of prM viral protein in
the virions.
NS3 Viral Protein is Present Inside GCs
Since we identified the NS3 viral protein inside DLNs of skin-
infected mice (Figure 1), we wanted to know then whether we
could localize this Ag precisely inside the GCs.We thus co-labeled
DLN cryosections for GCs (PNA labeling) and for NS3 viral Ag.
We detected NS3 inside GCs at day 7, 14, and 28 post-inoculation
(Figures 6A–F). However, at 28 days the positive signal was scarce
(Figures 6E,F).Wedetected double positive cells forNS3 andPNA
in situ, indicative that putative GC B cells contain the NS3 Ag.
Then, using flow cytometry from DLN cell suspensions, we fur-
ther looked for NS3-specific GC B cells at day 14 post-inoculation
(Figure 6G), we found an increased quantity of NS3-specific GCB
FIGURE 5 | Specific GC B cells and Ab responses to the viral proteins
prM and E. DLN from mice inoculated with different stimuli were harvested at
day 14 to prepare cell suspensions. Using multimers made of prM- or E-viral
proteins, we searched for Ag-specific GC B cells by flow citometry. (A) Total
specific GC B cells per antigenic protein per LN show a higher number for
prM-specific GC B cells than for E-specific GC B cells. Data shown are
pooled from two independent experiments, represent the meanSEM, and
were analyzed with two-way ANOVA with the Bonferroni post-test. *P<0.05,
**P<0.01, ***P<0.001. (B) Specific (IgG) Ab titers were determined for prM
and E viral Ags, DENV induces a bigger quantity of them in comparison with
iDENV. Data represent the meanSEM of the titers minus the titers of
control C6/36, and are representative from two independent experiments.
Mice were inoculated at day 0 and boosted at day 7.6= DENV_E vs iDENV_E,
and DENV_E vs iDENV_prM P<0.05; DENV_prM vs iDENV_E, and
DENV_prM vs iDENV_prM P<0.001 & DENV_E vs iDENV_prM
P<0.05; DENV_E vs iDENV_E P<0.01; DENV_E vs DENV_prM, DENV_prM
vs iDENV_E, and DENV_prM vs iDENV_prM P<0.001.
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FIGURE 6 | NS3 viral protein is present inside GCs in DLNs. Viral NS3
protein was identified in situ (DAB, brown color) in a double staining with GCs
(PNA, blue-gray color) in DLN at day 7 (A,B), 14 (C,D), and 28 (E,F)
post-DENV-inoculation. Positive cells were found inside GCs. For each time
point, right images [60, scale bar 40 µm; (B,D,F)] are derived from left
indicated squares [10, scale bar 200 µm; (A,C,E)]. Data are representative
from three independent experiments. Dotted lines indicate the limits of LNs.
(G) NS3-specific GC B cells at day 14 post-inoculation by flow cytometry
using multimers of NS3 viral protein. Data shown are pooled from two
independent experiments, represent the meanSEM, and were analyzed
with two-way ANOVA with the Bonferroni post-test. **P<0.01, ***P<0.001.
Mice were inoculated at day 0 and boosted at day 7.
cells in DENV-inoculated animals compared with the other con-
ditions.Mock-infected animals (i.e., immunizedwith iDENV) did
not show any positive signal for NS3 (Figure S4 in Supplementary
Material).
Discussion
Most animal models of diseases are developed trying to under-
stand the mechanisms of such diseases, and therefore should be
suited for studies of pathogenesis, pre-clinical testing of drugs,
and vaccines, among others. Regarding DENV infection, themost
used experimental models in vivo rely on immune-deficient mice
(33, 43); however, to assess precisely the intact immune responses,
these animals might not be the best indicated model. Although
the mouse does not manifest dengue disease like that in humans,
there are some studies done in immune-competent mice (29).
These models maintain virus replication, but high doses of DENV
are administered and can kill immune-competent BALB/c mice.
On the other hand, DENV is inoculated by different routes other
than the skin (30–32). Here, we propose an in vivo model in
immune-competent BALB/c mice based on cutaneous inocula-
tion, as the DENV infection occurs in nature. We were able to
infect mice by intradermal injection of relatively low doses of
the virus (6 104 pfu), as this dose approximates the one that
has been calculated that mosquitoes inoculate into their hosts
in wildlife (44), while the reported models use higher doses of
virus to cause the disease, even in immune-deficient mice (29,
33, 43). Between 7 and 28 days of DENV-skin inoculation, we
found the viral protein NS3 inside DLN, indicative that the virus
is indeed infecting immune-competent BALB/c mice. Although
during the first weekmice seemed to be in discomfort and showed
some piloerection, they did not exhibit other signs of dengue-like
disease. Altogether our findings suggest that at relatively low
doses, immune-competent animals become infected via the skin
but seem to clear the infection, and they do not present other
ostensible manifestations of dengue-like disease.
The study of the potential involvement of DENV Ags in the
induction and development of GCs has been rather neglected
during DENV infection; and, to our knowledge, there are no
reports regarding the GC response to DENV. Very few studies
about DENV Ags in murine LN have been reported describing
the pathology and the distribution of viral Ags; as an example,
groups of mononuclear cells containing viral Ag at the periphery
of the follicles have been described (29). Even for other viruses,
there are few reports of Ags inside GCs, for instance, Vesicular
Stomatitis Virus, Rauscher Leukemia Virus (45, 46), and a recent
studywithmurine gammaherpesvirus 68 revealed infection of GC
B cells (47). In the DENV infection in humans, the presence of
viral Ags has been reported inside lymphoid organs obtained from
fatal cases. Positive cells for DENV proteins have been found in
blast cells inside B cell follicles, PCs, and B cells in spleen and
LNs (48). The presence of positive-strand viral RNA has been
related with viral replication in GC B cells (49). Specifically, NS3
viral protein has been reported in LNs, but other studies were
not able to detect it (50, 51). On the other hand, it has been
described that the E and the NS1 protein depict a reticular pattern
inside GCs from spleen and LN (50). This pattern of DENV Ags
distribution is consistent with our findings, where NS3, prM, and
E viral proteins inside GCs exhibit also a reticular pattern. Our
results and those of other researchers showing DENV Ags inside
lymphoid tissues from both humans and mice suggest a potential
relationship between these Ags and the induction of GC reactions.
However, this issue has not been evaluated.
The production of memory Abs before a secondary antigenic
exposure occurs constitute an evolutionary and powerful strategy
to cope with subsequent infections, this may allow the neutral-
ization of a given pathogen before the secondary infection is
established (52). Memory Abs are usually generated through GC
responses; nevertheless, the involvement of GCs during DENV
infection is unknown and has not been assessed. By IHC and
flow cytometry, we found that in immune-competent mice, active
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DENV is inducing larger GCs than the other experimental condi-
tions, even larger than those triggered by a non-infectious protein,
and well-known inducer of GCs such as OVA. Intact DENV can
indeed infect immune-competentmicewhen administered via the
skin at a relatively low dose, and can actively trigger the formation
of GCs. Our results revealed that active DENV is a potent inducer
of GC responses.
In addition to similar quantities of NS3, prM, and E viral
proteins inside GCs in situ; by flow cytometry, we found com-
parable quantities of GC B cells specific for these viral Ags, even
significantly higher amounts of prM-specific GC B cells than for
the E protein.Datawere consistentwith higher quantities ofAbs to
prM than to E viral Ag.We think that DENV could bemodulating
the humoral response to preferentially promote the production
of Abs against certain viral Ags. In turn, these Abs might favor
a subsequent heterologous infection by facilitating the invasion
of host cells, as Abs to prM have been demonstrated to enhance
heterologous DENV infections (3, 4). This non-neutralizing Ab
responses seem to be dominant in humans (4, 16, 17) and MBC
encoding enhancing Abs predominate in the circulation, even two
or more decades following DENV infection (28). The presence
of the NS3 inside GCs could indicate that DENV is infecting
B cells.
Although Abs to E viral protein have been described as neu-
tralizers, it has been recently known that these Abs constitute
only a small fraction of the anti-DENVbinding and neutralization
activity in human immune sera (4, 16, 17, 42, 53). In addition,
most anti-E Abs are directed toward the EDI/EDII region and
can enhance the infection at sub-neutralizing concentrations (16,
27, 28). The recent characterization of human Abs obtained by
strategies to enrich neutralizing Ab-producing cells from periph-
eral blood mononuclear cells has made evident a variety of non-
neutralizing Abs. Several of them exhibit a remarkable activity to
enhance the infection (27). Moreover, Abs to all domains in the E
protein can render immatureDENVparticles infectious in a furin-
dependent manner (18). Interestingly, the most potent neutral-
izing serotype-specific Abs bound either to EDIII or to complex
epitopes found only on the intact viral particle (20, 26, 27). Since
our findings suggest that the response to prM may be similar to,
or even higher than the one to the E protein, this may imply that
DENVevolved to induce amixture ofAbswith facilitating features
in order to enhance the probabilities of subsequent infections.
These Abs could be directed to both prM and the E viral proteins.
Germinal center responses to cutaneous DENV infection in
immune-competent animalsmight be driven by defined viral pro-
teins which would induce non-neutralizing Abs; these Abs could
then enhance the infection of other target cells. This animalmodel
can be used to evaluate the in vivo humoral immune response
to DENV and the different viral Ags. We consider important to
understand the in vivo biology of these cellular responses for
making better designs and public health planning in the fight
against DENV infection.
Author Contributions
Conceived and designed the experiments: JY-P, LC-B, and LF-R.
Performed the experiments and the acquisition of data: JY-P,
JG-C, JC-A, and LD-M. Analyzed the data, interpretation, and
discussion: JY-P, LC-B, and LF-R. Wrote and revised the paper:
JY-P and LF-R. Final approval of the version to be published: LF-R.
Acknowledgments
Autors thank Drs. L. Santos-Argumedo, A. Escobar-Gutiérrez,
J. M. Hernandez-Hernandez, F. Navarro-Garcia, and V. F. Ortiz-
Navarrete for helpful discussions. JY-P and LD-M are fellow
holders from the National Council for Science and Technology
(CONACYT) Mexico. JG-C, JC-A, LC-B, and LF-R are members
of the National System of Researchers, SNI-CONACYT.
Supplementary Material
The Supplementary Material for this article can be found
online at http://journal.frontiersin.org/article/10.3389/fimmu.
2015.00188/abstract
References
1. WorldHealthOrganization.Dengue and Severe Dengue (2014) [cited 2014 July].
Available from: http://www.who.int/mediacentre/factsheets/fs117/en/
2. Halstead SB. Observations related to pathogenesis of dengue hemorrhagic fever.
VI. Hypotheses and discussion. Yale J Biol Med (1970) 42(5):350–62.
3. Huang K, Cheng Y, Lin Y, Huang J, Liu H, Yeh T, et al. Anti-prM antibody
as an autoantibody in dengue virus infection. Am J Infect Dis (2008) 4(1):
59–67.
4. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S,
Limpitikul W, et al. Cross-reacting antibodies enhance dengue virus infection
in humans. Science (2010) 328(5979):745–8. doi:10.1126/science.1185181
5. Junjhon J, Edwards TJ, Utaipat U, Bowman VD, Holdaway HA, Zhang W, et al.
Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus
particles. J Virol (2010) 84(16):8353–8. doi:10.1128/JVI.00696-10
6. van der Schaar HM, Rust MJ, Waarts BL, van der Ende-Metselaar H, Kuhn RJ,
Wilschut J, et al. Characterization of the early events in dengue virus cell entry
by biochemical assays and single-virus tracking. J Virol (2007) 81(21):12019–28.
doi:10.1128/JVI.00300-07
7. Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, Chipman
PR, et al. Structure of the immature dengue virus at low pH primes
proteolytic maturation. Science (2008) 319(5871):1834–7. doi:10.1126/science.
1153264
8. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, et al.
Structure of dengue virus: implications for flavivirus organization, maturation,
and fusion. Cell (2002) 108(5):717–25. doi:10.1016/S0092-8674(02)00660-8
9. Perera R, Kuhn RJ. Structural proteomics of dengue virus. Curr Opin Microbiol
(2008) 11(4):369–77. doi:10.1016/j.mib.2008.06.004
10. Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, Chen J, et al. The flavivirus precursor
membrane-envelope protein complex: structure andmaturation. Science (2008)
319(5871):1830–4. doi:10.1126/science.1153263
11. Zhang Y, Corver J, Chipman PR, Zhang W, Pletnev SV, Sedlak D, et al.
Structures of immature flavivirus particles. EMBO J (2003) 22(11):2604–13.
doi:10.1093/emboj/cdg270
12. Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der
Ende-Metselaar H, Lei HY, Wilschut J, et al. Immature dengue virus: a
veiled pathogen? PLoS Pathog (2010) 6(1):e1000718. doi:10.1371/journal.ppat.
1000718
13. Schmidt AC. Response to dengue fever – the good, the bad, and the ugly?NEngl
J Med (2010) 363(5):484–7. doi:10.1056/NEJMcibr1005904
14. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glyco-
protein from tick-borne encephalitis virus at 2 A resolution. Nature (1995)
375(6529):291–8. doi:10.1038/375291a0
15. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue
virus E glycoprotein are the most efficient blockers of virus adsorption to vero
cells. J Virol (2001) 75(16):7769–73. doi:10.1128/JVI.75.16.7769-7773.2001
Frontiers in Immunology | www.frontiersin.org April 2015 | Volume 6 | Article 1888
Yam-Puc et al. GCs following cutaneous DENV infection
16. BeltramelloM,Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT,
et al. The human immune response to dengue virus is dominated by highly
cross-reactive antibodies endowed with neutralizing and enhancing activity.
Cell Host Microbe (2010) 8(3):271–83. doi:10.1016/j.chom.2010.08.007
17. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus
A, et al. In-depth analysis of the antibody response of individuals exposed to
primary dengue virus infection. PLoS Negl Trop Dis (2011) 5(6):e1188. doi:10.
1371/journal.pntd.0001188
18. da Silva Voorham JM, Rodenhuis-Zybert IA, Ayala Nunez NV, Colpitts TM,
van der Ende-Metselaar H, Fikrig E, et al. Antibodies against the envelope
glycoprotein promote infectivity of immature dengue virus serotype 2. PLoS
One (2012) 7(3):e29957. doi:10.1371/journal.pone.0029957
19. Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus enve-
lope protein after membrane fusion. Nature (2004) 427(6972):313–9. doi:10.
1038/nature02165
20. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM,
et al. Identification of human neutralizing antibodies that bind to complex
epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 109(19):7439–44.
doi:10.1073/pnas.1200566109
21. Jacob J, Kelsoe G, Rajewsky K, Weiss U. Intraclonal generation of antibody
mutants in germinal centres. Nature (1991) 354(6352):389–92. doi:10.1038/
354389a0
22. MacLennan IC.Germinal centers.AnnuRev Immunol (1994) 12:117–39. doi:10.
1146/annurev.iy.12.040194.001001
23. Nieuwenhuis P, Opstelten D. Functional anatomy of germinal centers. Am J
Anat (1984) 170(3):421–35. doi:10.1002/aja.1001700315
24. Benner R, Hijmans W, Haaijman JJ. The bone marrow: the major source of
serum immunoglobulins, but still a neglected site of antibody formation. Clin
Exp Immunol (1981) 46(1):1–8.
25. BachmannMF, Kundig TM, Odermatt B, Hengartner H, Zinkernagel RM. Free
recirculation of memory B cells versus antigen-dependent differentiation to
antibody-forming cells. J Immunol (1994) 153(8):3386–97.
26. Friberg H, Jaiswal S, West K, O’Ketch M, Rothman AL, Mathew A. Analysis of
human monoclonal antibodies generated by dengue virus-specific memory B
cells. Viral Immunol (2012) 25(5):348–59. doi:10.1089/vim.2012.0010
27. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE Jr. Isolation
of dengue virus-specific memory B cells with live virus antigen from human
subjects following natural infection reveals the presence of diverse novel func-
tional groups of antibody clones. J Virol (2014) 88(21):12233–41. doi:10.1128/
JVI.00247-14
28. Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, Crowe JE
Jr. Persistence of circulating memory B cell clones with potential for dengue
virus disease enhancement for decades following infection. J Virol (2011)
86(5):2665–75. doi:10.1128/JVI.06335-11
29. Boonpucknavig S, Vuttiviroj O, Boonpucknavig V. Infection of young adult
mice with dengue virus type 2. Trans R Soc Trop Med Hyg (1981) 75(5):647–53.
doi:10.1016/0035-9203(81)90142-5
30. Huang KJ, Li SY, Chen SC, Liu HS, Lin YS, Yeh TM, et al. Manifestation of
thrombocytopenia in dengue-2-virus-infected mice. J Gen Virol (2000) 81(Pt
9):2177–82.
31. Paes MV, Pinhao AT, Barreto DF, Costa SM, Oliveira MP, Nogueira AC, et al.
Liver injury and viremia in mice infected with dengue-2 virus. Virology (2005)
338(2):236–46. doi:10.1016/j.virol.2005.04.042
32. Raut CG, Deolankar RP, Kolhapure RM, Goverdhan MK. Susceptibility of
laboratory-bred rodents to the experimental infection with dengue virus type
2. Acta Virol (1996) 40(3):143–6.
33. Zompi S, Harris E. Animal models of dengue virus infection. Viruses (2012)
4(1):62–82. doi:10.3390/v4010062
34. Limon-Flores AY, Perez-Tapia M, Estrada-Garcia I, Vaughan G, Escobar-
Gutierrez A, Calderon-Amador J, et al. Dengue virus inoculation to human
skin explants: an effective approach to assess in situ the early infection and
the effects on cutaneous dendritic cells. Int J Exp Pathol (2005) 86(5):323–34.
doi:10.1111/j.0959-9673.2005.00445.x
35. Russell PK, Nisalak A. Dengue virus identification by the plaque reduction
neutralization test. J Immunol (1967) 99(2):291–6.
36. Mellado-Sanchez G, Garcia-Machorro J, Sandoval-Montes C, Gutierrez-
Castaneda B, Rojo-Dominguez A, Garcia-Cordero J, et al. A plasmid encod-
ing parts of the dengue virus E and NS1 proteins induces an immune
response in a mouse model. Arch Virol (2010) 155(6):847–56. doi:10.1007/
s00705-010-0652-x
37. Garcia-Cordero J, Ramirez HR, Vazquez-Ochoa M, Gutierrez-Castaneda B,
Santos-Argumedo L, Villegas-Sepulveda N, et al. Production and characteriza-
tion of a monoclonal antibody specific for NS3 protease and the ATPase region
of dengue-2 virus. Hybridoma (Larchmt) (2005) 24(3):160–4. doi:10.1089/hyb.
2005.24.160
38. Katrak K, Mahon BP, Jones WC, Brautigam S, Mills KH. Preparative separation
of foreign antigens for highly efficient presentation to T cells in vitro. J Immunol
Methods (1992) 156(2):247–54. doi:10.1016/0022-1759(92)90032-O
39. Taylor JJ, Martinez RJ, Titcombe PJ, Barsness LO, Thomas SR, Zhang N, et al.
Deletion and anergy of polyclonal B cells specific for ubiquitous membrane-
bound self-antigen. J Exp Med (2012) 209(11):2065–77. doi:10.1084/jem.
20112272
40. Bartholomeusz AI, Wright PJ. Synthesis of dengue virus RNA in vitro: ini-
tiation and the involvement of proteins NS3 and NS5. Arch Virol (1993)
128(1–2):111–21. doi:10.1007/BF01309792
41. Erbel P, Schiering N, D’Arcy A, RenatusM, KroemerM, Lim SP, et al. Structural
basis for the activation of flaviviral NS3 proteases from dengue and West Nile
virus. Nat Struct Mol Biol (2006) 13(4):372–3. doi:10.1038/nsmb1073
42. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM.
Dengue virus neutralization by human immune sera: role of envelope protein
domain III-reactive antibody. Virology (2009) 392(1):103–13. doi:10.1016/j.
virol.2009.06.037
43. Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing.
J Virol (1999) 73(1):783–6.
44. Styer LM, Kent KA, Albright RG, Bennett CJ, Kramer LD, Bernard KA.
Mosquitoes inoculate high doses of West Nile virus as they probe and
feed on live hosts. PLoS Pathog (2007) 3(9):1262–70. doi:10.1371/journal.ppat.
0030132
45. BachmannMF,Odermatt B,HengartnerH, Zinkernagel RM. Induction of long-
lived germinal centers associated with persisting antigen after viral infection. J
Exp Med (1996) 183(5):2259–69. doi:10.1084/jem.183.5.2259
46. Hanna MG Jr, Szakal AK, Tyndall RL. Histoproliferative effect of Rauscher
leukemia virus on lymphatic tissue: histological and ultrastructural studies
of germinal centers and their relation to leukemogenesis. Cancer Res (1970)
30(6):1748–63.
47. Collins CM, Speck SH. Tracking murine gammaherpesvirus 68 infection of
germinal center B cells in vivo. PLoS One (2012) 7(3):e33230. doi:10.1371/
journal.pone.0033230
48. Bhoopat L, Bhamarapravati N, Attasiri C, Yoksarn S, Chaiwun B, Khu-
namornpong S, et al. Immunohistochemical characterization of a new mon-
oclonal antibody reactive with dengue virus-infected cells in frozen tissue
using immunoperoxidase technique. Asian Pac J Allergy Immunol (1996)
14(2):107–13.
49. Jessie K, Fong MY, Devi S, Lam SK, Wong KT. Localization of dengue virus
in naturally infected human tissues, by immunohistochemistry and in situ
hybridization. J Infect Dis (2004) 189(8):1411–8. doi:10.1086/383043
50. Aye KS, Charngkaew K, Win N, Wai KZ, Moe K, Punyadee N, et al. Pathologic
highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar.
Hum Pathol (2014) 45(6):1221–33. doi:10.1016/j.humpath.2014.01.022
51. Balsitis SJ, Coloma J, Castro G, Alava A, Flores D, McKerrow JH, et al. Tropism
of dengue virus in mice and humans defined by viral nonstructural protein
3-specific immunostaining. Am J Trop Med Hyg (2009) 80(3):416–24.
52. Steinhoff U, Muller U, Schertler A, Hengartner H, Aguet M, Zinkernagel
RM. Antiviral protection by vesicular stomatitis virus-specific antibodies in
alpha/beta interferon receptor-deficient mice. J Virol (1995) 69(4):2153–8.
53. Schieffelin JS, Costin JM, Nicholson CO, Orgeron NM, Fontaine KA, Isern S,
et al. Neutralizing and non-neutralizing monoclonal antibodies against dengue
virus E protein derived from a naturally infected patient. Virol J (2010) 7:28.
doi:10.1186/1743-422X-7-28
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Yam-Puc, García-Cordero, Calderón-Amador, Donis-Maturano,
Cedillo-Barrón and Flores-Romo. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordancewith
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org April 2015 | Volume 6 | Article 1889
